Today, 2 pharmaceutical companies are listed on the market, starting a new journey

【Pharmaceutical Network Pharmaceutical Stock Market】 Today, there are two enterprises listed in the pharmaceutical field, of which Enwei Pharmaceutical is listed on the Shenzhen Stock Exchange, and the public offering of 17.
54 million shares, of which 17.
54 million shares are publicly issued, the issue price is 29.
80 yuan / share, the new shares raise 523 million yuan, and the total share capital after the issuance is 70.
138359 million shares
.

Nuo Cheng Jianhua was listed on the Shanghai Stock Exchange, and the number of shares issued this time was 265 million shares, accounting for about 15% of the total share capital of the company after the issuance, and the issue price was 11.
03 yuan per share
.

According to the data, Enwei Pharmaceutical is mainly engaged in the research and development, production and sales of proprietary Chinese medicines and chemical drugs, focusing on gynecological products, pediatric drugs, respiratory system drugs and other fields
.

In this listing, Enwei Pharmaceutical intends to raise 701 million yuan for the reconstruction and expansion project of Sichuan Enwei Pharmaceutical and the construction project
of Qamdo headquarters.

From the perspective of investment project planning, the Sichuan expansion project is conducive to Enwei Pharmaceutical to further enhance the advanced level of technology, and the Qamdo headquarters project is conducive to strengthening the company's grasp
of the whole industrial chain of traditional Chinese medicine.

The industry said that Enwei Pharmaceutical, which is listed today, as a deep cultivator in the field of proprietary Chinese medicine, deserves the attention
of investors.

On the one hand, the development of the Chinese medicine industry is supported by policies, with a certain performance growth and valuation cost-effectiveness, the overall industry is ushering in a period of rapid development, and the plate is expected to usher in a valuation repair market
.

On the other hand, Enwei Pharmaceutical has a variety of products that demonstrate continuous "hematopoietic" ability
.

It is understood that in recent years, the sales of Enwei Pharmaceutical gynecological products, pediatric drugs, respiratory drugs and other products have continued to improve, and the operating income and net profit attributable to the mother have maintained a steady growth trend
.

According to its prospectus, from 2019 to 2021, Enwei Pharmaceutical's operating income increased from 615 million yuan to 676 million yuan; net profit attributable to the mother increased from 82.
592 million yuan to 102 million yuan; gross profit margin remained stable at more than 55% in the past three years, and good gross profit margin also showed the competitiveness of its products and better profitability
.

Another company listed today, Nuocheng Jianhua is an innovative biopharmaceutical company focused on areas with huge unmet clinical needs, such as oncology and autoimmune diseases, to develop drugs
with breakthrough potential in the global market.

It is reported that the total amount of funds raised by Nuocheng Jianhua in this offering is 2,919,069,800 yuan, which is used for new drug research and development projects, drug research and development platform upgrade projects, marketing network construction projects, information construction projects, and supplementary working capital
.

At present, Nuocheng Jianhua has built an integrated biomedical platform, taking into account the needs of R&D quality and R&D speed, and establishing a product pipeline
with a high balance of innovation and risk, covering a number of popular targets with market prospects.

Among them, the core product obbutinib (Enokai) was conditionally approved by the State Food and Drug Administration in December 2020 for two indications
for patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and relapsed/refractory mantle cell lymphoma (MCL).

In addition, 13 products are in Phase I/II/III clinical trials, and many products are in the preclinical stage
.

According to the data, in terms of research and development, in 2019-2021, the amount of R&D investment was 234 million yuan, 423 million yuan and 732 million yuan, respectively, and the proportion of R&D expenses in 2021 was as high as 70.
25% of the total revenue, and the cumulative investment in R&D expenses in three years was nearly 1.
4 billion yuan
.

Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.